308 related articles for article (PubMed ID: 31322269)
1. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
2. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
3. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
4. CHFR is important for the first wave of ubiquitination at DNA damage sites.
Liu C; Wu J; Paudyal SC; You Z; Yu X
Nucleic Acids Res; 2013 Feb; 41(3):1698-710. PubMed ID: 23268447
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
6. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.
Kashima L; Idogawa M; Mita H; Shitashige M; Yamada T; Ogi K; Suzuki H; Toyota M; Ariga H; Sasaki Y; Tokino T
J Biol Chem; 2012 Apr; 287(16):12975-84. PubMed ID: 22337872
[TBL] [Abstract][Full Text] [Related]
7. Activation of the SNF2 family ATPase ALC1 by poly(ADP-ribose) in a stable ALC1·PARP1·nucleosome intermediate.
Gottschalk AJ; Trivedi RD; Conaway JW; Conaway RC
J Biol Chem; 2012 Dec; 287(52):43527-32. PubMed ID: 23132853
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
9. Structure and dynamics of the chromatin remodeler ALC1 bound to a PARylated nucleosome.
Bacic L; Gaullier G; Sabantsev A; Lehmann LC; Brackmann K; Dimakou D; Halic M; Hewitt G; Boulton SJ; Deindl S
Elife; 2021 Sep; 10():. PubMed ID: 34486521
[TBL] [Abstract][Full Text] [Related]
10. Kaposi's sarcoma-associated herpesvirus processivity factor (PF-8) recruits cellular E3 ubiquitin ligase CHFR to promote PARP1 degradation and lytic replication.
Chung WC; Lee S; Kim Y; Seo JB; Song MJ
PLoS Pathog; 2021 Jan; 17(1):e1009261. PubMed ID: 33508027
[TBL] [Abstract][Full Text] [Related]
11. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
[TBL] [Abstract][Full Text] [Related]
12. Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein.
Kulkarni A; Oza J; Yao M; Sohail H; Ginjala V; Tomas-Loba A; Horejsi Z; Tan AR; Boulton SJ; Ganesan S
J Biol Chem; 2013 Nov; 288(45):32357-32369. PubMed ID: 23926104
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Insights into Autoinhibition of the Oncogenic Chromatin Remodeler ALC1.
Lehmann LC; Hewitt G; Aibara S; Leitner A; Marklund E; Maslen SL; Maturi V; Chen Y; van der Spoel D; Skehel JM; Moustakas A; Boulton SJ; Deindl S
Mol Cell; 2017 Dec; 68(5):847-859.e7. PubMed ID: 29220652
[TBL] [Abstract][Full Text] [Related]
14. The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Juhász S; Smith R; Schauer T; Spekhardt D; Mamar H; Zentout S; Chapuis C; Huet S; Timinszky G
Sci Adv; 2020 Dec; 6(51):. PubMed ID: 33355125
[TBL] [Abstract][Full Text] [Related]
15. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
16. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
17. Multiple roles for PARP1 in ALC1-dependent nucleosome remodeling.
Ooi SK; Sato S; Tomomori-Sato C; Zhang Y; Wen Z; Banks CAS; Washburn MP; Unruh JR; Florens L; Conaway RC; Conaway JW
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34465625
[TBL] [Abstract][Full Text] [Related]
18. A Poly-ADP-Ribose Trigger Releases the Auto-Inhibition of a Chromatin Remodeling Oncogene.
Singh HR; Nardozza AP; Möller IR; Knobloch G; Kistemaker HAV; Hassler M; Harrer N; Blessing C; Eustermann S; Kotthoff C; Huet S; Mueller-Planitz F; Filippov DV; Timinszky G; Rand KD; Ladurner AG
Mol Cell; 2017 Dec; 68(5):860-871.e7. PubMed ID: 29220653
[TBL] [Abstract][Full Text] [Related]
19. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
20. PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1.
Pines A; Vrouwe MG; Marteijn JA; Typas D; Luijsterburg MS; Cansoy M; Hensbergen P; Deelder A; de Groot A; Matsumoto S; Sugasawa K; Thoma N; Vermeulen W; Vrieling H; Mullenders L
J Cell Biol; 2012 Oct; 199(2):235-49. PubMed ID: 23045548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
